Aberrant overexpression of membrane-associated mucin MUC1 is implicated in the pathogenesis of cancer, particularly of adenocarcinomas.
Introduction
Mucins are high molecular weight glycoproteins expressed at the apical borders of secretory epithelial cells [1] . The membrane-associated mucin MUC1 (also known as RP11-263K19.2, CD227, EMA, H23AG, KL-6, MAM6, PEM, PEMT, or PUM) represents a type I transmembrane glycoprotein and consists of 3 domains; a large extracellular domain containing a tandem repeat domain, transmembrane domains that are highly conserved among species, and a short cytoplasmic tail (CT) that was recently found to correlate with signal transduction [2; 3] . The biological functions of MUC1 are the lubrication and hydration of cell surfaces as well as protection from microorganisms and degradative enzymes [1] . In addition, MUC1 is implicated in the pathogenesis of cancer, particularly of adenocarcinomas [4; 5] , and increased concentrations of mucin-type glycoproteins in serum are basically correlated to increasing tumour burden and a poor prognosis [6; 7] . Although the precise mechanism regulating the adhesive or anti-adhesive effect of MUC1 is unknown, the anti-adhesive effect may be exerted by blocking cell-cell and cell-extracellular matrix interactions [8] . This property of MUC1 confers migrational and metastatic capabilities to tumour cells [9] .
The detection of the epithelial membrane antigen (EMA) in plasma cells and some lymphomas was first described in the early 1980s [10; 11] .
Accumulated evidence indicates that myeloma cells express MUC1, making MUC1 a potential molecular target in the treatment of myeloma [12; 13; 14] . However, the implications of MUC1 expression for disease Adult T-cell Leukaemia/Lymphoma (ATL), an aggressive neoplasm etiologically associated with human T-lymphotropic virus type-1 (HTLV-1), is resistant to treatment [15; 16] . ATL, with 4 clinical subtypes; acute, chronic, smoldering and lymphoma, is known to have diversity in clinico-pathological features [17] . Until recently, ATL was thought to derive from a subset of helper/inducer T-cells, but evidence is now accumulating that ATL cells originate from regulatory T-cells (Treg cells) naturally expressing CD4, CD25, CCR4, CCR8, CD30, GITR, and Foxp3 [18; 19; 20] . This well explains the characteristic clinical features of ATL, such as severe immunodeficiency and invasive tropism of tumour cells into skin, given the properties of Treg cells . However, ATL cells also tend to invade lung, liver, spleen, brain, and bone and grow co-adhesively [21; 22] . In the present study, we found that MUC1 is overexpressed at the levels of mRNA and protein in ATL cells and involved in cell-growth, cell aggregation, and resistance to apoptosis. This represents the first report of the expression and functions of MUC1 in ATL cells.
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Patients and samples
A total of 64 patients with ATL, 52 with acute-type ATL and 12 with chronic-type ATL, and 10 healthy donors were included in this study. The diagnosis of ATL was based on clinical features, haematological findings including cytologically or histologically proven mature T-cell leukaemia/lymphoma, and serum anti-HTLV-1 antibodies, and monoclonal HTLV-1 provirus integration into the genome was confirmed by Southern blot hybridization in all cases [26] . The subclassification of ATL was made according to previously described criteria [17] . Peripheral blood mononuclear cells (PBMCs) from patients with ATL and healthy donors were purified by density gradient centrifugation using Lympho-prep (AXIS-SHIELD, Oslo, Norway). Each sample contained more than 90% leukaemia cells at the time of analysis. The study was approved by the Ethics Committee of Nagasaki University Hospital, and all materials from patients were obtained with informed consent.
Cell lines
The ATL-derived cell lines SO4, ST1, KK1, KOB, OMT, and LM-Y1 were established in our laboratory from sample of ATL patients [26; 27; 28; 29]. They were maintained in RPMI 1640 medium supplemented with 10% FBS and 0.5U/ml of IL-2 (kindly provided by Takeda Pharmaceutical Company, Ltd., Osaka, Japan). We also used the HTLV-1-infected T-cell 5'-GTGCCCCCTAGCAGTACCG-3', antisense:
5'-GACGTGCCCCTACAAGTTGG-3', and TaqMan probe: 6FAM-AGCCCCTATGAGAAGGTTTCTGCAGGTAATG-TAMRA [32] . All data were normalized to the level of GAPDH measured in the same sample.
Flow cytometric analysis
The cell surface expression of MUC1 was examined by flow cytometry Fund Laboratories, London, UK) [33] . Mouse IgG1 (DAKO Japan,
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Kyoto, Japan) and FITC-conjugated goat anti-mouse IgG1 (DAKO Japan)
were used as a negative control and as a secondary antibody, respectively.
PBMCs from ATL patients and healthy donors were stained further with anti-CD25 PE (BD), anti-CD19 PE (BD) and/or anti-CD4 perCP (BD). 
CD4
Immunocytochemistry
Cells smeared on glass slides were fixed with 4% paraformaldehyde at 4°C for 15 min and then stained with anti-MUC1/CD227 antibody for 2 hours at room temperature after permeabilization using a commercial kit (BD). The slides were counter-stained with Hoechst 33258 for staining of the nucleus (Molecular Probe Inc., Eugene, OR, USA). Signals were fluoroscopically observed using Leica DM4000B Microsystems (Mannheim, Germany) and the fluorescence images were collected and analyzed with a Leica AF6000 Application Suite.
Small interfering RNA experiments
Transfection was performed with a Cell line Nucleofector kit V and the NucleofectorTM system (Lonza, Cologne, Germany). The transfection programs for KOB (T-16) and KK1 (T-20) were determined so that the
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viability of cells and the transfection efficiency would be compatible.
Twenty four hours after transfection, the cells were processed for FCM, a cell proliferation assay, a homotypic adhesion assay, or an evaluation for apoptosis. We prepared three different small interfering RNA (siRNA) against MUC1; Silencer Select pre-designed siRNA s9065, s9066, and s9067 and control siRNA (Silencer negative control #1) (Applied Biosystems, Foster City, CA, USA). After evaluating the effect of each siRNA by monitoring the target's mRNA and protein, we eventually selected siRNA s9065.
Statistical analysis
Survival was analyzed using the Kaplan-Meier method, with the log rank test used to calculate the significance of differences. Other data were statistically analyzed based on Student's t-test, and differences were recognized as significant if the p value was less than 0.05 or 0.01. The results were expressed as the mean ± standard deviation (SD).
Results
ATL cell lines have high levels of MUC1
We (Figure 2A ).
Among 64 ATL cases, 30 each with high and low levels of MUC1 mRNA were chosen. Then we compared survival periods between the two groups.
The group with high levels of MUC1 mRNA had significantly shorter survival times ( Figure 2B ). Unexpectedly however, there was no significant difference between acute type cells and chronic type cells in MUC1 mRNA expression ( Figure 2A ). These results suggest the expression of MUC1 mRNA to be a prognostic marker for ATL.
Representative data on the cell surface protein expression of MUC1 in normal CD4-positive lymphocytes, chronic ATL cells, and acute type ATL cells are shown in Figure 2C . Interestingly, acute type cells showed significantly higher levels of MUC1 protein than chronic type cells, and there was no difference between chronic type cells and normal PBMCs ( Figure 2D ).
MUC1 contributes to the cell proliferation in ATL cell lines
We performed knockdown experiments using siRNA for MUC1
(si-MUC1) to investigate the role of MUC1 in cell proliferation. Effects of si-MUC1 on mRNA levels were well documented within 24 hours and continued after 72 hours ( Figure 3A ). As shown, the cell surface expression of MUC1 was also suppressed by si-MUC1 in KOB and KK1 cells ( Figure 3B ). In this setting, we performed cell proliferation assays up to the 96 hour mark, comparing si-MUC1 cells and si-control cells.
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The inhibition of cell growth in si-MUC1 cells at 96 hours was approximately 25% and 30% of that in KOB and KK1 cells, respectively ( Figure 3C ). These results suggest that MUC1 contributes to cell growth in ATL cell lines. Figure 4B ).
In contrast, si-MUC1 cells caused less aggregation, resulting in an increase in non-aggregated cells to 80% and 64% of that for KOB and KK1 cells, respectively (closed bars in Figure 4B ). These results suggest that MUC1
contributes to the aggregation of these cells.
MUC1 inhibits apoptosis in ATL cells
A recent report indicated that MUC1 attenuates apoptotic responses such as TRAIL-induced apoptosis in some types of cancer cells [42] .
Previously, we showed that ATL cells are resistant to TRAIL though they have TRAIL death-receptors [26] . We then investigated whether the MUC1 of ATL cells influences the resistance to TRAIL-induced apoptosis.
Si-control and si-MUC1 cells of the KOB and KK1 lines were treated with 400ng/mL of TRAIL, and Annexin-V/PI staining was performed.
Si Figure 5C ).
Discussion
In the present study, we revealed that MUC1 is overexpressed exclusively in ATL cells. The aberrant overexpression is implicated in the pathogenesis of ATL and makes MUC1 a potential molecular target in the treatment of ATL.
MUC1 expression had been thought to be restricted to epithelial cells, however, non-epithelial expression of MUC1 has recently been described in haematological malignancies such as myelomas [43] , B-cell lymphomas [44] , anaplastic large cell lymphomas [45] , and acute myelogeneous leukaemia (AML) [46] . expression has been studied in normal peripheral blood and hematopoietic tissues [47; 48; 49] . In regard to peripheral blood cells, one previous report showed the constitutive expression of MUC1 mRNA and an absence of MUC1 protein at the cell surface in resting human T cells [35] .
Another study found that MUC1 was undetectable by RT-PCR or Northern blotting in resting T cells and the level of MUC1 expression in activated human T cells was low [50] . Our results indicated that normal PBMCs have quite low levels of MUC1 mRNA and that normal CD4 lymphocytes have only marginal amounts of MUC1 at the cell surface. These discrepancies remain to be explained and the profiles of MUC1 expression in normal peripheral blood seem to be controversial.
We previously investigated the serum levels of Krebs von den Lungen-6 (KL-6) in patients with haematological malignancies and found them to be high in some cases without pulmonary complications, most of which were ATL cases, and closely related to the stage of ATL [51] . In the present study, most chronic type ATL cells had upregulated mRNA expression but low levels MUC1 at the cell surface. These results are not necessarily contradictory. Acute type ATL cells may acquire the cell surface expression of MUC1 during their transformation. Since the precise mechanism by which MUC1 is overexpressed in cancer cells remains unknown [52] , ATL cells may serve as a model.
The aberrant overexpression of MUC1 has been thought to contribute to tumour progression by affecting cell adhesion and cell recognition [9] .
The anti-adhesive properties of MUC1 inhibit cell-cell and cell-matrix contact and facilitate the migration and metastasis of tumour cells [41] . This new concept helps to explain the mechanism of MUC1-mediated cancer cell growth [56; 57] . Another MUC1-mediated effect is resistance to apoptosis [42] . Recent studies suggest that MUC1 suppresses apoptosis through the regulation of JNK, NF-κB, HSP90, and extrinsic apoptotic pathways [58] . It was also demonstrated that MUC1 CT bounds directly to the p53 regulatory domain and suppressed the p53-dependent apoptotic response [59] . Our results showed no enhancement of Nutlin-3a-induced apoptosis by si-MUC1, however, we found that si-MUC1 enhanced TRAIL-and MG132-induced apoptosis in cells with both wild-type (KOB) and mutant (KK1) p53. These results indicate that MUC1 expression correlates with resistance to apoptosis in ATL cells, via a mechanism not entirely dependent on p53. Since TRAIL-induced apoptosis plays a role in cancer immuno-surveillance [60] , ATL cells may evade attack by using this anti-recognition property of MUC1.
In conclusion, we found MUC1 to be overexpressed 
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